Search

everythinglearnresearchcommunity

for

Search:↓

Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.

Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.

Herbal drugs show promise for treating alopecia with fewer side effects, but standardization is challenging.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.

Finasteride and dutasteride do not significantly change beard thickness in men.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Men taking dutasteride may have a higher risk of age-related macular degeneration.

Three natural compounds from Ghanaian plants may help treat BPH and alopecia.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.

Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.

Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.